{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:38Z","timestamp":1786998398794,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009067","name":"K. Albin Johansson Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009067","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Finnish Cultural Fund"},{"name":"National Graduate School of Clinical Investigation"},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ygyno.2013.06.015","type":"journal-article","created":{"date-parts":[[2013,6,15]],"date-time":"2013-06-15T19:46:34Z","timestamp":1371325594000},"page":"463-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma"],"prefix":"10.1016","volume":"130","author":[{"given":"Jutta","family":"Huvila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri","family":"Talve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Carp\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Henrik","family":"Edqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Pont\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seija","family":"Gr\u00e9nman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Auranen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.06.015_bb0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/IGC.0b013e3181995f90","article-title":"Endometrial cancer state of the science meeting","volume":"19","author":"Kitchener","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/GRF.0b013e318218c6d1","article-title":"Recurrent endometrial cancer","volume":"54","author":"Del Carmen","year":"2011","journal-title":"Clin Obstet Gynecol"},{"issue":"Suppl. 6","key":"10.1016\/j.ygyno.2013.06.015_bb0015","doi-asserted-by":"crossref","first-page":"vi35","DOI":"10.1093\/annonc\/mdr374","article-title":"Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Colombo","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0020","author":"NCCN"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0025","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(09)70290-6","article-title":"Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009","volume":"10","author":"Tangjitgamol","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0030","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/0002-9378(85)90671-4","article-title":"Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma","volume":"151","author":"Creasman","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0035","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cncr.2820710411","article-title":"Prognostic significance of hormone receptors in endometrial cancer","volume":"71","author":"Creasman","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/gyno.1998.5023","article-title":"Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma","volume":"69","author":"Fukuda","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0090-8258(90)90012-A","article-title":"Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance","volume":"38","author":"Kleine","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/gyno.1993.1211","article-title":"Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients","volume":"50","author":"Kadar","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2008.10.032","article-title":"Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer","volume":"112","author":"Jongen","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s004280000361","article-title":"Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression","volume":"438","author":"Sivridis","year":"2001","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0065","author":"NCI."},{"key":"10.1016\/j.ygyno.2013.06.015_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/gyno.2000.5751","article-title":"Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma","volume":"77","author":"Silverman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0075","first-page":"4667","article-title":"Prognostic significance of p53 overexpression in endometrial cancer","volume":"54","author":"Ito","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0080","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.1999.17.5.1382","article-title":"Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study","volume":"17","author":"Salvesen","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0085","first-page":"2779","article-title":"Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas","volume":"4","author":"Salvesen","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0090","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0046-8177(03)00246-6","article-title":"Molecular pathology of atypical polypoid adenomyoma of the uterus","volume":"34","author":"Ota","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0095","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ygyno.2009.12.028","article-title":"Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer","volume":"117","author":"Resnick","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0090-8258(02)00094-X","article-title":"HER2\/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?","volume":"88","author":"Santin","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/PAI.0b013e31817c645e","article-title":"Evaluation of monospecific antibodies: a comparison study with commercial analogs using immunohistochemistry on tissue microarrays","volume":"16","author":"Paavilainen","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0110","first-page":"e3620","article-title":"Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas","volume":"63","author":"Kampf","year":"2012","journal-title":"J Vis Exp"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0115","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/jcp.2006.040170","article-title":"Validation of tissue microarray technology in endometrioid cancer of the endometrium","volume":"60","author":"Fons","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0120","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1349-7006.2006.00332.x","article-title":"Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma","volume":"97","author":"Saito","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0125","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.anndiagpath.2006.06.009","article-title":"Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women","volume":"11","author":"Norimatsu","year":"2007","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0135","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ejca.2010.02.031","article-title":"Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG)","volume":"46","author":"Mackay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.tem.2011.01.005","article-title":"Progesterone: the ultimate endometrial tumor suppressor","volume":"22","author":"Yang","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0145","doi-asserted-by":"crossref","first-page":"e30840","DOI":"10.1371\/journal.pone.0030840","article-title":"Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer","volume":"7","author":"van der Horst","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0150","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/modpathol.2010.91","article-title":"Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies","volume":"23","author":"Folkins","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2005.04.024","article-title":"Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer","volume":"98","author":"Ferrandina","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0160","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/IGC.0b013e3181d80ac4","article-title":"Selected immunohistochemical prognostic factors in endometrial cancer","volume":"20","author":"Markova","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ygyno.2003.12.038","article-title":"A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma","volume":"93","author":"Oreskovic","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.06.015_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2011.07.030","article-title":"Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-A clinical and pathological evaluation","volume":"124","author":"Voss","year":"2012","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813008482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813008482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:33:55Z","timestamp":1758771235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813008482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0090825813008482"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.06.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}